Mostrar el registro sencillo del ítem

Artículo

dc.creatorArgüelles Arias, Federicoes
dc.creatorGuerra Veloz, María Fernandaes
dc.creatorPerea Amarillo, Raúles
dc.creatorVilches Arenas, Ángeles
dc.creatorCastro Laria, Luisaes
dc.creatorMaldonado Pérez, Belénes
dc.creatorMerino Bohórquez, Vicente
dc.creatorRomero Gómez, Manuel
dc.date.accessioned2019-02-26T18:25:36Z
dc.date.available2019-02-26T18:25:36Z
dc.date.issued2017
dc.identifier.citationArgüelles Arias, F., Guerra Veloz, M.F., Perea Amarillo, R., Vilches Arenas, Á., Castro Laria, L., Maldonado Pérez, B.,...,Romero Gómez, M. (2017). Switching from reference infliximab to CT-P13 in patients with inflammatory bowel disease: 12 months results. European Journal of Gastroenterology & Hepatology, 29 (11), 1290-1295.
dc.identifier.issn1473-5687es
dc.identifier.urihttps://hdl.handle.net/11441/83530
dc.description.abstractBackground: Biological agents, such as infliximab, have transformed the outcomes of patients with immune-mediated inflammatory diseases. The advent of biosimilar treatment options such as CT-P13 promises to improve the availability of biological therapy, yet real-world switching data are currently limited. Here, we assess the effectiveness and safety of switching to CT-P13 from infliximab reference product (RP) in patients with inflammatory bowel disease. Materials and methods: This was a prospective single-center observational study in patients with moderate to severe Crohn’s disease (CD) and ulcerative colitis (UC). All patients were switched from infliximab RP (Remicade) to CT-P13 treatment and followed up for up to 12 months. The efficacy endpoint was the change in clinical response assessed at 3-monthly intervals, according to the Harvey–Bradshaw score and partial Mayo score for patients with CD and UC, respectively. C-reactive protein (CRP) was also measured. Adverse events were monitored and recorded throughout the study. Results: A total of 98 patients with inflammatory bowel disease (67 CD/31 UC) were included. A total of 83.6% (56/67) of patients with CD were in remission at the time of the switch and 62.7% were in remission at 12 months. The Harvey–Bradshaw score showed a significant change at 12 months (P =0.007) but no significant change was observed in median CRP at this timepoint (P= 0.364). A total of 80.6% (25/31) of patients with UC were in remission at the time of the switch and 65.3% (18/28) were in remission at 12 months. No significant changes in the median partial Mayo score (P=0.058) or CRP (P =0.329) were observed at 12 months. Serious adverse events related to medication were reported in 11 (11.2%) patients. Conclusion: Switching from infliximab RP to CT-P13 is efficacious and well tolerated in patients with CD or UC for up to 12 months.es
dc.formatapplication/pdfes
dc.language.isoenges
dc.publisherLippincott Williams & Wilkinses
dc.relation.ispartofEuropean Journal of Gastroenterology & Hepatology, 29 (11), 1290-1295.
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectBiosimilar agentes
dc.subjectCrohn’s diseasees
dc.subjectCT-P13es
dc.subjectInflammatory bowel diseasees
dc.subjectInfliximabes
dc.subjectUlcerative colitises
dc.titleSwitching from reference infliximab to CT-P13 in patients with inflammatory bowel disease: 12 months resultses
dc.typeinfo:eu-repo/semantics/articlees
dcterms.identifierhttps://ror.org/03yxnpp24
dc.type.versioninfo:eu-repo/semantics/publishedVersiones
dc.rights.accessrightsinfo:eu-repo/semantics/openAccesses
dc.contributor.affiliationUniversidad de Sevilla. Departamento de Medicinaes
dc.identifier.doi10.1097/MEG.0000000000000953es
dc.contributor.groupUniversidad de Sevilla. CTS-532 Unidad de Hepatologiaes
idus.format.extent6es
dc.journaltitleEuropean Journal of Gastroenterology & Hepatologyes
dc.publication.volumen29es
dc.publication.issue11es
dc.publication.initialPage1290es
dc.publication.endPage1295es

FicherosTamañoFormatoVerDescripción
Switching.pdf219.6KbIcon   [PDF] Ver/Abrir   Swithching

Este registro aparece en las siguientes colecciones

Mostrar el registro sencillo del ítem

Attribution-NonCommercial-NoDerivatives 4.0 Internacional
Excepto si se señala otra cosa, la licencia del ítem se describe como: Attribution-NonCommercial-NoDerivatives 4.0 Internacional